
Servier and MiNA Therapeutics sign €220m deal
Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

Two companies aim for 2nd-gen COVID vaccines
As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

BioPhero A/S raises US$17m in Series A funding
New investor exFMC Ventures, as well as existing investors Syngenta Group Ventures and Novo Holdings also participated in the...

AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...

Roche in take-over deal with GenMark Diagnostics
The US$1.8bn cash merger – US$ 24.05 per share – is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s...

Germany orders antibody therapies from USA
Although there is no centralised approval required for biologics from the European Medicines Agency, Germany's Health Minister Jens Spahn has...

Endeavour Medtech Growth II LP closes at $375m
The fund will pursue the strategy to support innovative growth-stage medtech and digital health companies.Both new and returning investors supported...